Ceritinib, marketed as Zykadia® by Novartis, is an approved targeted therapy for anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) patients. The gene discussed is ALK; the disease is non-small cell lung carcinoma.